Candel Therapeutics To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024

6/11/24 8:22:36 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CADL alert in real time by email

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Get the next $CADL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CADL

Date	Price Target	Rating	Analyst
12/2/2022	$11.00	Buy	H.C. Wainwright
11/19/2021	$18.00	Outperform	BMO Capital
8/23/2021	$9.00	Buy	UBS
8/23/2021	$22.00	Buy	Jefferies
8/23/2021	$15.00	Outperform	Credit Suisse

More analyst ratings

$CADL
Market Insights

Live Market Insights

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
7/18/24 1:36:38 PM ET
$CADL
$CRBP
$DAVE
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Why BioRestorative Therapies Stock Is Moving Higher Thursday
BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed commercial regenerative medicine company. What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property. Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders.
6/13/24 11:52:46 AM ET
$BRTX
$CADL
Managed Health Care
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Candel Therapeutics To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
6/11/24 8:22:36 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
9/4/24 8:00:00 AM ET
$CADL
$EBS
$MIST
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Candel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitaliza
6/11/24 8:00:00 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
NEEDHAM, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced the appointment of Nicoletta Loggia, PhD, RPh, to the Company's Board of Directors (Board) effective June 7, 2023. "We are pleased to welcome Nicoletta as a new member of Candel's Board," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel. "Her wealth of strategic and hands-on industry experience in drug development and manufacturing makes her an important addition to our Board as we advance our late-
6/8/23 8:00:00 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024On track for topline progression-free survival data from the phase 2b randomized controlled clinical trial of CAN-2409 in the active surveillance population with localized low/intermediate risk prostate cancer, expected in Q4 2024Presented preclinical data on therapeutic potential of CAN-3110 in melanoma at the SITC 2024 Annual MeetingThe Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan to the end of Q1 2025 NEEDHAM, Mass., Nov. 14, 2024 (GLO
11/14/24 8:00:00 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
NEEDHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference 2024, being held on November 19-21, 2024. Date: Wednesday, November 20, 2024Time: 9:30-9:55AM GMT / 4:30-4:55AM ESTWebcast Link: https://wsw.com/webcast/jeff315/cadl/1810704 A webcast of the presentation will be available by selecting Events and Presentations under the News & Events t
11/7/24 8:00:00 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanomaCAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activationFindings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumor NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological imm
11/5/24 9:00:32 AM ET
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Candel Therapeutics To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024

Chat with this insight

Recent Analyst Ratings for $CADL

$CADL Financials

Live finance-specific insights

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

$CADL Market Insights

Live Market Insights

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing

Why BioRestorative Therapies Stock Is Moving Higher Thursday